# Se‐Hoon Lee

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/se-hoon-lee/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,338 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 87 |
| i10-index | 427 |
| Last Known Institution | Yong In University |
| OpenAlex ID | https://openalex.org/A5066161983 |
| ORCID iD | 0000-0002-9219-3350 |
| Works | 1,141 |

## Researcher papers

Showing 12 of 23.

- [Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma](https://scholariq.org/papers/single-cell-rna-sequencing-demonstrates-the-molecular-and-cellular-reprogramming/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/)
- [Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition](https://scholariq.org/papers/meta-analysis-of-tumor-and-t-cell-intrinsic-mechanisms-of-sensitization-to/)
- [Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort](https://scholariq.org/papers/antitumor-activity-of-pembrolizumab-in-biomarker-unselected-patients-with/)
- [Lung adenocarcinoma promotion by air pollutants](https://scholariq.org/papers/lung-adenocarcinoma-promotion-by-air-pollutants/)
- [The transcriptional landscape and mutational profile of lung adenocarcinoma](https://scholariq.org/papers/the-transcriptional-landscape-and-mutational-profile-of-lung-adenocarcinoma/)
- [Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial](https://scholariq.org/papers/safety-and-efficacy-of-sunitinib-for-metastatic-renal-cell-carcinoma-an-expanded/)
- [DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load](https://scholariq.org/papers/dna-methylation-loss-promotes-immune-evasion-of-tumours-with-high-mutation-and/)
- [Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas](https://scholariq.org/papers/clonal-history-and-genetic-predictors-of-transformation-into-small-cell/)
- [Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)](https://scholariq.org/papers/osimertinib-for-patients-with-non-small-cell-lung-cancer-harboring-uncommon-egfr/)
- [Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial](https://scholariq.org/papers/pembrolizumab-for-patients-with-refractory-or-relapsed-thymic-epithelial-tumor/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Yong In University](https://scholariq.org/institutions/yong-in-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.